These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 30243723)
1. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells. Chang Y; Park KH; Lee JE; Han KC Biochem Biophys Res Commun; 2018 Oct; 505(1):187-193. PubMed ID: 30243723 [TBL] [Abstract][Full Text] [Related]
2. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093 [TBL] [Abstract][Full Text] [Related]
3. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055 [TBL] [Abstract][Full Text] [Related]
4. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. McDermott MS; Browne BC; Conlon NT; O'Brien NA; Slamon DJ; Henry M; Meleady P; Clynes M; Dowling P; Crown J; O'Donovan N Mol Cancer; 2014 Jun; 13():157. PubMed ID: 24958351 [TBL] [Abstract][Full Text] [Related]
5. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234 [TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941 [TBL] [Abstract][Full Text] [Related]
7. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Sethunath V; Hu H; De Angelis C; Veeraraghavan J; Qin L; Wang N; Simon LM; Wang T; Fu X; Nardone A; Pereira R; Nanda S; Griffith OL; Tsimelzon A; Shaw C; Chamness GC; Reis-Filho JS; Weigelt B; Heiser LM; Hilsenbeck SG; Huang S; Rimawi MF; Gray JW; Osborne CK; Schiff R Mol Cancer Res; 2019 Nov; 17(11):2318-2330. PubMed ID: 31420371 [TBL] [Abstract][Full Text] [Related]
8. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616 [TBL] [Abstract][Full Text] [Related]
9. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051 [TBL] [Abstract][Full Text] [Related]
10. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148 [TBL] [Abstract][Full Text] [Related]
11. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Rexer BN; Ham AJ; Rinehart C; Hill S; Granja-Ingram Nde M; González-Angulo AM; Mills GB; Dave B; Chang JC; Liebler DC; Arteaga CL Oncogene; 2011 Oct; 30(40):4163-74. PubMed ID: 21499296 [TBL] [Abstract][Full Text] [Related]
12. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439 [TBL] [Abstract][Full Text] [Related]
13. miR-221 confers lapatinib resistance by negatively regulating p27 Huynh TK; Huang CH; Chen JY; Yao JH; Yang YS; Wei YL; Chen HF; Chen CH; Tu CY; Hsu YM; Liu LC; Huang WC Cancer Sci; 2021 Oct; 112(10):4234-4245. PubMed ID: 34382727 [TBL] [Abstract][Full Text] [Related]
14. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705 [TBL] [Abstract][Full Text] [Related]
16. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280 [TBL] [Abstract][Full Text] [Related]
17. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022 [TBL] [Abstract][Full Text] [Related]
18. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells. Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049 [TBL] [Abstract][Full Text] [Related]
19. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053 [TBL] [Abstract][Full Text] [Related]
20. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. Borrero-García LD; Del Mar Maldonado M; Medina-Velázquez J; Troche-Torres AL; Velazquez L; Grafals-Ruiz N; Dharmawardhane S BMC Cancer; 2021 Jun; 21(1):652. PubMed ID: 34074257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]